Announcements Trials
Browse Landscape

Status

Completed 2Unknown 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Uterine Cervical Neoplasms 1NSCLC 1Lung Neoplasms 1Leukemia, Myeloid, Chronic-Phase 1Endometrial Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1

Interventions

durvalumab 18Bevacizumab 17atezolizumab 13lenvatinib 10Magnetic Resonance Spectroscopy 10tremelimumab 8Nivolumab 8pembrolizumab 7Sorafenib 6Specimen Handling 5camrelizumab 4cabozantinib 4Immunoglobulin G 4Disulfides 4sintilimab 3apatinib 3X-Rays 3Radiotherapy 3Radiofrequency Ablation 3Radiation 3Hepatectomy 3E-7386 3Doxorubicin 3Cyclophosphamide 3tislelizumab 2relatlimab 2dostarlimab 2budigalimab 2Standard of Care 2Simvastatin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Carcinoma, Hepatocellular × Tyrosine Kinase Inhibitors × Clear all
NCT06632106 2024-10-08

HAIC in Combination with Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors for Advanced HCC

First Hospital of China Medical University

Active not recruiting
97 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡